SAN DIEGO – January 05, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced the appointments of Ciara Kennedy, Ph.D. to President and Chief Executive Officer (CEO) and Karen Joy Shaw, Ph.D., to Chief Scientific Officer (CSO). In conjunction with this announcement, the company’s former President and CEO, […]
By: David Nicklaus Source: St. Louis Post-Dispatch Date: December 2, 2016 When RiverVest Venture Partners opened its doors in 2000, hopes were high that it would be an important funding source for St. Louis’ nascent biotechnology industry. RiverVest went on to be a highly successful venture capital firm, managing $290 million and demonstrating a knack […]
ST. LOUIS, MO (Nov. 30, 2016) – Life sciences venture capital firm RiverVest Venture Partners today announced the closing of Archer Seed Fund, L.P. at $15 million.
Long-term collaboration for US distribution of Tryton Side Branch Stent pending regulatory approval. DURHAM, NC – October 27, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies have established a long-term strategic […]
ST. LOUIS, MO (Sept. 16, 2016) – Tioma Therapeutics, Inc., a RiverVest portfolio company developing therapies to treat solid and blood-based cancers, announced it has raised $86 million in Series A venture financing. The Series A financing included early investor RiverVest along with Novo Ventures, GlaxoSmithKline’s corporate venture arm S.R. One, Limited and new investors, Roche […]